Evaluation of hypertension as a marker of bevacizumab efficacy - Wikidata - wikimedia - TriplyDB

Evaluation of hypertension as a marker of bevacizumab efficacy

Evaluation of hypertension as a marker of bevacizumab efficacy

http://www.wikidata.org/entity/Q36991546

about

Critical appraisal of sorafenib in the treatment of Chinese patients with renal cell carcinoma Correlation of bevacizumab-induced hypertension and outcomes of metastatic colorectal cancer patients treated with bevacizumab: a systematic review and meta-analysis Prevalence of hypertension and type 2 diabetes mellitus in patients with colorectal cancer and their median survival time: A cohort study.Anthrax lethal toxin suppresses high glucose induced VEGF over secretion through a post-translational mechanism.Anti-VEGF therapies in the clinic Angiotensin II type-1 receptor blockers enhance the effects of bevacizumab-based chemotherapy in metastatic colorectal cancer patients.Analysis of early hypertension and clinical outcome with bevacizumab: results from seven phase III studies.In vivo RAF signal transduction as a potential biomarker for sorafenib efficacy in patients with neuroendocrine tumours.Modeling efficacy of bevacizumab treatment for metastatic colon cancer.VEGF remains an interesting target in advanced pancreas cancer (APCA): results of a multi-institutional phase II study of bevacizumab, gemcitabine, and infusional 5-fluorouracil in patients with APCA.Prognostic factors for survival with bevacizumab-based therapy in colorectal cancer patients: a systematic review and pooled analysis of 11,585 patients.Treatment-related Hypertension as a Pharmacodynamic Biomarker for the Efficacy of Bevacizumab in Advanced Pancreas Cancer: A Pooled Analysis of 4 Prospective Trials of Gemcitabine-based Therapy With Bevacizumab.Prevention of fostamatinib-induced blood pressure elevation by antihypertensive agents.Predictors of anti-VEGF drug-induced hypertension using different hypertension criteria: a secondary analysis of the COMPARZ study.Genetic and ethnic modulation of cardiovascular toxicity of vascular endothelial growth factor inhibitors.Genetic variants in the renin-angiotensin system predict response to bevacizumab in cancer patients.Association between bevacizumab-related hypertension and response to treatment in patients with metastatic colorectal cancer.Hypertension in malignancy-an underappreciated problem.

P2860

Q33754122-804D1D73-E359-4FCD-99C7-A8295A5AB056 Q34455292-121E2466-02C3-45C8-B79B-475D5E054975 Q34716000-3362F12C-B5EB-4A73-9DD8-8AD841D094A0 Q35691890-1140B3B5-ED4E-4AAF-A0CB-86C8990350F0 Q36330281-BF8A9206-A360-4003-8BF2-9E8EC15E83BD Q36335456-D8CD9359-6754-4D47-8C75-D0FA20C84D3C Q36714379-26AC866A-F64E-4B08-A6FA-8466FC04083F Q36747337-075AA327-E66A-41C3-A4E5-1784424FA1F2 Q36845505-96634EF9-BB3A-4B32-AD6D-DBA3BC46E25D Q37345045-4C690EEC-3472-4942-BC85-50FF067BC116 Q38312076-4B607594-B08C-44B6-BDE2-22CB51DE8270 Q41978345-6F6DE7B8-5180-4EF2-A924-F98FCDD84DA8 Q43203308-CD602DE7-6DAC-4EDD-9DDE-64E107DA81C0 Q49635743-5EBDDCC0-E994-487C-B0E4-AB8643FCFC24 Q49997360-2D9DC8C3-4BF4-4406-8869-4F1D7C64E8CF Q53303141-D3A027BA-6571-4200-ABEE-DC6F9DAAD2D8 Q54647675-E7F59869-F82F-43B5-A4B6-C71C997DDE9F Q55071881-9F0151E1-6452-4431-A2A6-B68A489D7AE5

P2860

Evaluation of hypertension as a marker of bevacizumab efficacy

http://www.wikidata.org/entity/Q36991546

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

2009年论文

@zh

2009年论文

@zh-cn

name

Evaluation of hypertension as a marker of bevacizumab efficacy

@en

type

label

Evaluation of hypertension as a marker of bevacizumab efficacy

@en

prefLabel

Evaluation of hypertension as a marker of bevacizumab efficacy

@en

P1433

Q36991546-930E8E47-6F68-4A1B-8DE7-9566FFF43D79

P1476

Q36991546-145A4CFF-2A71-4BFC-A273-E20A167316B3

P2093

Q36991546-3BA21738-0579-4653-A49D-21D580D31C83

Q36991546-42415BC5-0A2A-4A7B-99E4-0C8A60CE96FF

Q36991546-61C81749-A618-4D25-8F4C-BDEB43CA5068

Q36991546-99518C14-30A1-42D9-905F-3137ED1B62E7

Q36991546-A4E0326C-A9DD-41AD-89D2-17F6A9DEA655

Q36991546-C9E52A5B-BB7C-4C75-A8CC-4D417A941B08

P2860

Q36991546-028BE56A-03A1-4A7C-9D7C-15622F6CD747

Q36991546-0C9BDAA8-2E4B-4036-A706-EEEF9D381357

Q36991546-161770BA-1DCD-479C-9515-E2FF02EDBD33

Q36991546-253BE542-9F85-443C-98C6-7B8BA7B4C22E

Q36991546-6470FD2F-8AC1-4455-A3B9-6E505B4C3A94

Q36991546-6A5D27DF-7FDA-4B78-AE3E-5289424CFE97

Q36991546-6CE3D1B2-0894-4A65-A61A-47FAD33A7717

Q36991546-7F152A53-5C12-41A5-8816-6BE8950B13C4

Q36991546-81691579-C984-4037-9C4D-EEC2A2E86262

Q36991546-9932503F-A938-4DC1-B0DB-53093C718A9F

P2888

Q36991546-C5BFE6C9-6688-475C-ADCC-DEAC9CE65FAF

P304

Q36991546-96544790-FDED-4346-A299-0A8D196E5AD6

P31

Q36991546-5D84B220-E40F-4F38-90A6-47EE9096C440

P356

Q36991546-D75C2ABB-EF9E-4F24-BDAE-BDDC19D30191

P433

Q36991546-D600911B-82E6-48AD-A523-9002364D3185

P478

Q36991546-75E80A15-DABD-4D66-97CB-A06362C3D3E2

P577

Q36991546-EBB78440-1D34-498A-AA54-85F4F4FAE204

P5875

Q36991546-C4133D4B-2493-4E49-8FE2-64478484B1B9

P698

Q36991546-C677DF61-5F52-4F19-B517-309CE5B680FD

P921

Q36991546-9F231FAC-FC3F-48DE-BCBE-C4B09428ACB9

P932

Q36991546-50A6D186-65D5-4CB8-974F-2DDED84B8B1A

P356

S12029-009-9104-9

P1433

Journal of gastrointestinal cancer

P1476

Evaluation of hypertension as a marker of bevacizumab efficacy

@en

P2093

Aiwu R He

http://www.w3.org/2001/XMLSchema#string

Anne-Michelle Noone

http://www.w3.org/2001/XMLSchema#string

John L Marshall

http://www.w3.org/2001/XMLSchema#string

Peter A Lindenberg

http://www.w3.org/2001/XMLSchema#string

Rebecca Slack

http://www.w3.org/2001/XMLSchema#string

Rebekah Ryanne Wu

http://www.w3.org/2001/XMLSchema#string

P2860

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab.

Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation.

Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer.

Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study.

Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study.

Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.

Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer.

Dermatologic side effects associated with the epidermal growth factor receptor inhibitors.

Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis.

P2888

s12029-009-9104-9

P304

101-108

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S12029-009-9104-9

http://www.w3.org/2001/XMLSchema#string

P433

3-4

http://www.w3.org/2001/XMLSchema#string

P478

40

http://www.w3.org/2001/XMLSchema#string

P577

2009-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

38097230

http://www.w3.org/2001/XMLSchema#string

P698

19921473

http://www.w3.org/2001/XMLSchema#string

P921

P932

3704163

http://www.w3.org/2001/XMLSchema#string